Literature DB >> 31363057

A large case-control study on vaccination as risk factor for multiple sclerosis.

Alexander Hapfelmeier1, Christiane Gasperi1, Ewan Donnachie1, Bernhard Hemmer2.   

Abstract

OBJECTIVE: To investigate the hypothesis that vaccination is a risk factor for multiple sclerosis (MS) by use of German ambulatory claims data in a case-control study.
METHODS: Using the ambulatory claims data of the Bavarian Association of Statutory Health Insurance Physicians covering 2005-2017, logistic regression models were used to assess the relation between MS (n = 12,262) and vaccinations in the 5 years before first diagnosis. Participants newly diagnosed with Crohn disease (n = 19,296) or psoriasis (n = 112,292) and participants with no history of these autoimmune diseases (n = 79,185) served as controls.
RESULTS: The odds of MS were lower in participants with a recorded vaccination (odds ratio [OR] 0.870, p < 0.001 vs participants without autoimmune disease; OR 0.919, p < 0.001 vs participants with Crohn disease; OR 0.973, p = 0.177 vs participants with psoriasis). Lower odds were most pronounced for vaccinations against influenza and tick-borne encephalitis. These effects were consistently observed for different time frames, control cohorts, and definitions of the MS cohort. Effect sizes increased toward the time of first diagnosis.
CONCLUSIONS: Results of the present study do not reveal vaccination to be a risk factor for MS. On the contrary, they consistently suggest that vaccination is associated with a lower likelihood of being diagnosed with MS within the next 5 years. Whether this is a protective effect needs to be addressed by future studies.
© 2019 American Academy of Neurology.

Entities:  

Year:  2019        PMID: 31363057     DOI: 10.1212/WNL.0000000000008012

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

1.  Vaccination Coverage against Tetanus, Diphtheria, Pertussis and Poliomyelitis and Validity of Self-Reported Vaccination Status in Patients with Multiple Sclerosis.

Authors:  Silvan Elias Langhorst; Niklas Frahm; Michael Hecker; Pegah Mashhadiakbar; Barbara Streckenbach; Julia Baldt; Felicita Heidler; Uwe Klaus Zettl
Journal:  J Pers Med       Date:  2022-04-23

Review 2.  Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis.

Authors:  H P Hartung; C Warnke; F Schweitzer; S Laurent; G R Fink; Michael H Barnett
Journal:  J Neurol       Date:  2020-02-08       Impact factor: 4.849

Review 3.  [The corona pandemic and multiple sclerosis: vaccinations and their implications for patients-Part 2: vaccine technologies].

Authors:  Tobias Monschein; Tobias Zrzavy; Micha Löbermann; Alexander Winkelmann; Thomas Berger; Paulus Rommer; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nervenarzt       Date:  2021-07-07       Impact factor: 1.297

4.  Tick-borne encephalitis vaccination in multiple sclerosis: A prospective, multicenter study.

Authors:  Alexander Winkelmann; Christoph Metze; Silvius Frimmel; Emil C Reisinger; Uwe K Zettl; Micha Loebermann
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-01-09

5.  Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data.

Authors:  Samantha Epstein; Zongqi Xia; Annie J Lee; Megan Dahl; Keith Edwards; Elle Levit; Erin E Longbrake; Christopher Perrone; Katelyn Kavak; Bianca Weinstock-Guttman; Fatoumata Diallo; Adelle Ricci; Claire S Riley; Philip L De Jager; Rebecca Farber; Sarah F Wesley
Journal:  Mult Scler Relat Disord       Date:  2021-12-02       Impact factor: 4.339

Review 6.  Vaccination and immunotherapies in neuroimmunological diseases.

Authors:  Alexander Winkelmann; Micha Loebermann; Michael Barnett; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2022-04-06       Impact factor: 44.711

7.  First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.

Authors:  Joachim Havla; Yannick Schultz; Hanna Zimmermann; Reinhard Hohlfeld; Adrian Danek; Tania Kümpfel
Journal:  J Neurol       Date:  2021-06-11       Impact factor: 4.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.